Advertisement
New Zealand markets closed
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NZD/USD

    0.5936
    +0.0002 (+0.04%)
     
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • OIL

    83.13
    -0.23 (-0.28%)
     
  • GOLD

    2,328.50
    -13.60 (-0.58%)
     

Considering AbbVie’s 2018 Expense Projections

Considering AbbVie’s 2018 Expense Projections

In the third quarter, AbbVie (ABBV) reported SG&A (selling, general, and administrative) expenses of $1.57 billion, a YoY (year-over-year) rise of 8.77%. However, its adjusted SG&A as a percentage of its total revenue was 19.1% in the third quarter, a YoY improvement of 170 basis points. According to AbbVie’s third-quarter earnings conference call, the company benefited from improved operational efficiencies and sales leverage in the quarter.